FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2264753802> ?p ?o ?g. }

• W2264753802 endingPage "15007" @default.
• W2264753802 startingPage "15007" @default.
• W2264753802 abstract "15007 Background: Pmab, a fully human monoclonal antibody against the epidermal growth factor receptor, is approved in the US for the tx of pts with refractory mCRC. This randomized study examined differences between pre-emptive and reactive skin tx for ST associated with pmab therapy. Methods: Pts with unresectable mCRC and disease progression whose 1st-line tx with CT± bevacizumab failed were enrolled. Pts received Q2W FOLFIRI+pmab (6.0mg/kg) or Q3W irinotecan+pmab (9.0mg/kg). Within cohorts, pts were randomized 1:1 to pre-emptive ST tx (24 hrs prior to 1st pmab dose, daily through wk 6) or reactive tx (after ST developed). ST tx included use of skin moisturizers, sunscreen, topical corticosteroids, and oral doxycycline. The primary endpoint was incidence of specific ≥ grade (gr) 2 ST during the 6-wk skin tx period. This early analysis assessed pooled safety (data cutoff 06/07). Results: Of 58 pts with available data, 32 pts and 26 pts received the Q2W and Q3W regimens, respectively. Pts received a median of 7.5 (Q2W cohort) and 4.0 (Q3W cohort) doses of pmab and CT. Tx-related adverse events (AEs) were seen in 95% of pts; 62% had gr 3/4. AEs of interest are shown (table). Pmab dose reductions occurred in 6 pts (10%) due to ST; 19 pts had serious AEs; 2 pts ended the study because of an AE. Ten pts (31%) in the Q2W cohort and 1 pt (4%) in the Q3W cohort had an objective response to pmab. Planned enrollment of 95 pts has been completed; efficacy outcomes (pre-emptive vs reactive ST tx and objective response) by KRAS status for all pts will be presented. Conclusions: No safety issues were identified in this early analysis of pts receiving pmab + irinotecan-based CT. Pooled Analysis of Adverse Events (n = 58) AE Any grade, n (%) ≥ Grade 3, n (%) Skin Toxicity 51 (88) 13 (22) Infections * 42 (72) 13 (22) Diarrhea 40 (69) 8 (14) Nausea 31 (53) 4 (7) Neutropenia 16 (28) 9 (16) Dehydration 13 (22) 7 (12) Hypomagnesemia 10 (17) 3 (5) Deep venous thrombosis 2 (3) 2 (3) Pulmonary embolism 0 (0) 0 (0) Per MedDRA; grading based on CTCAEv3, modified for ST. * Includes rash pustular and paronychia No significant financial relationships to disclose." @default.
• W2264753802 created "2016-06-24" @default.
• W2264753802 creator A5015349477 @default.
• W2264753802 creator A5034912444 @default.
• W2264753802 creator A5035695580 @default.
• W2264753802 creator A5040844328 @default.
• W2264753802 creator A5052121797 @default.
• W2264753802 creator A5068275318 @default.
• W2264753802 creator A5070653944 @default.
• W2264753802 creator A5072917229 @default.
• W2264753802 creator A5083795244 @default.
• W2264753802 date "2008-05-20" @default.
• W2264753802 modified "2023-09-28" @default.
• W2264753802 title "A phase II, open-label trial of skin toxicity (ST) evaluation (STEPP) in metastatic colorectal cancer (mCRC) patients (pts) receiving panitumumab (pmab) + FOLFIRI or irinotecan-only chemotherapy (CT) as 2nd-line treatment (tx): Interim analysis" @default.
• W2264753802 doi "https://doi.org/10.1200/jco.2008.26.15_suppl.15007" @default.
• W2264753802 hasPublicationYear "2008" @default.
• W2264753802 type Work @default.
• W2264753802 sameAs 2264753802 @default.
• W2264753802 citedByCount "10" @default.
• W2264753802 countsByYear W22647538022012 @default.
• W2264753802 crossrefType "journal-article" @default.
• W2264753802 hasAuthorship W2264753802A5015349477 @default.
• W2264753802 hasAuthorship W2264753802A5034912444 @default.
• W2264753802 hasAuthorship W2264753802A5035695580 @default.
• W2264753802 hasAuthorship W2264753802A5040844328 @default.
• W2264753802 hasAuthorship W2264753802A5052121797 @default.
• W2264753802 hasAuthorship W2264753802A5068275318 @default.
• W2264753802 hasAuthorship W2264753802A5070653944 @default.
• W2264753802 hasAuthorship W2264753802A5072917229 @default.
• W2264753802 hasAuthorship W2264753802A5083795244 @default.
• W2264753802 hasConcept C121608353 @default.
• W2264753802 hasConcept C126322002 @default.
• W2264753802 hasConcept C141071460 @default.
• W2264753802 hasConcept C197934379 @default.
• W2264753802 hasConcept C203092338 @default.
• W2264753802 hasConcept C2776694085 @default.
• W2264753802 hasConcept C2776705615 @default.
• W2264753802 hasConcept C2777793932 @default.
• W2264753802 hasConcept C2777802072 @default.
• W2264753802 hasConcept C2778375690 @default.
• W2264753802 hasConcept C2778715236 @default.
• W2264753802 hasConcept C2780259306 @default.
• W2264753802 hasConcept C526805850 @default.
• W2264753802 hasConcept C535046627 @default.
• W2264753802 hasConcept C71924100 @default.
• W2264753802 hasConcept C72563966 @default.
• W2264753802 hasConceptScore W2264753802C121608353 @default.
• W2264753802 hasConceptScore W2264753802C126322002 @default.
• W2264753802 hasConceptScore W2264753802C141071460 @default.
• W2264753802 hasConceptScore W2264753802C197934379 @default.
• W2264753802 hasConceptScore W2264753802C203092338 @default.
• W2264753802 hasConceptScore W2264753802C2776694085 @default.
• W2264753802 hasConceptScore W2264753802C2776705615 @default.
• W2264753802 hasConceptScore W2264753802C2777793932 @default.
• W2264753802 hasConceptScore W2264753802C2777802072 @default.
• W2264753802 hasConceptScore W2264753802C2778375690 @default.
• W2264753802 hasConceptScore W2264753802C2778715236 @default.
• W2264753802 hasConceptScore W2264753802C2780259306 @default.
• W2264753802 hasConceptScore W2264753802C526805850 @default.
• W2264753802 hasConceptScore W2264753802C535046627 @default.
• W2264753802 hasConceptScore W2264753802C71924100 @default.
• W2264753802 hasConceptScore W2264753802C72563966 @default.
• W2264753802 hasIssue "15_suppl" @default.
• W2264753802 hasLocation W22647538021 @default.
• W2264753802 hasOpenAccess W2264753802 @default.
• W2264753802 hasPrimaryLocation W22647538021 @default.
• W2264753802 hasRelatedWork W2007060363 @default.
• W2264753802 hasRelatedWork W2084464231 @default.
• W2264753802 hasRelatedWork W2416369235 @default.
• W2264753802 hasRelatedWork W2590977625 @default.
• W2264753802 hasRelatedWork W2591743724 @default.
• W2264753802 hasRelatedWork W2597984509 @default.
• W2264753802 hasRelatedWork W2738360744 @default.
• W2264753802 hasRelatedWork W3000742518 @default.
• W2264753802 hasRelatedWork W3135413589 @default.
• W2264753802 hasRelatedWork W2313188235 @default.
• W2264753802 hasVolume "26" @default.
• W2264753802 isParatext "false" @default.
• W2264753802 isRetracted "false" @default.
• W2264753802 magId "2264753802" @default.
• W2264753802 workType "article" @default.